Poly(ADP-Ribose) Polymerase Inhibitors [MoA]

Purpose: To define the prevalence of HER2 positive breast cancer (HER2+ BC) in women with gBRCA1/2-BC and to determine whether… Expand

Introduction: Ovarian cancer is a rare but often fatal disease and a leading cause of gynecologic cancer death, in the United… Expand

OBJECTIVE Homologous recombination (HR)-proficient ovarian tumors have poorer clinical outcomes and show resistance to poly ADP… Expand

Epithelial ovarian cancer (EOC) is a common malignant disease, which remains asymptomatic for a prolonged period of time and is… Expand

Poly(ADP-ribose) polymerase inhibitors (PARPi) are targeted therapeutics with enhanced selectivity and cytotoxicity in BRCA1/2… Expand

Poly(ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and PARP2. Talazoparib, the most potent PARPI… Expand

Injury and inflammation lead to hypoxia and elevated lactate in wounds. This redox environment establishes cells in a reparative… Expand